Interpret a newborn screening (NBS) 17-hydroxyprogesterone (17-OHP) result for congenital adrenal hyperplasia (CAH) — including gestational-age and birth-weight adjusted cut-offs, when to repeat, when to run a second-tier LC-MS/MS multi-steroid profile, which CAH subtypes the screen will and will not detect, and the immediate clinical action plan for a screen-positive baby. Use when a clinician asks "is this 17-OHP positive", "what to do with a high NBS 17-OHP", "screen-positive CAH next step...
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill cah-nbs-17ohp-interpretation --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Cah Nbs 17ohp Interpretation?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-cah-nbs-17ohp-interpretation)More formats (shields.io, HTML) on the badges page.
---
name: cah-nbs-17ohp-interpretation
description: Interpret a newborn screening (NBS) 17-hydroxyprogesterone (17-OHP) result for congenital adrenal hyperplasia (CAH) — including gestational-age and birth-weight adjusted cut-offs, when to repeat, when to run a second-tier LC-MS/MS multi-steroid profile, which CAH subtypes the screen will and will not detect, and the immediate clinical action plan for a screen-positive baby. Use when a clinician asks "is this 17-OHP positive", "what to do with a high NBS 17-OHP", "screen-positive CAH next steps", "false positive NBS CAH preterm baby", "second tier CAH testing", "does NBS detect 11β-hydroxylase or 17α-hydroxylase deficiency", or any newborn screening 17-OHP interpretation question. Source: Balsamo A, et al. Frontiers in Pediatrics 2020;8:593315 (Newborn Screening section); cross-referenced with ICMR / IAP newborn screening recommendations and Speiser PW et al. Endocrine Society CPG 2018.
---
# CAH Newborn Screening (17-OHP) Interpreter
**Source:** Balsamo A et al., *Front Pediatr* 2020;8:593315 — Newborn Screening section; Dabas A et al., *Indian Pediatrics* 2020;57:159–164; ICMR Task Force NBS report 2018.
Scope: any baby with a dried-blood-spot (DBS) 17-OHP result from a newborn screening program. This skill covers interpretation and action — not the screening logistics themselves.
---
## STEP 1 — Know what NBS for CAH actually catches
NBS using DBS 17-OHP **detects classic CYP21A2 deficiency (21-OHD)** — the form responsible for ≥ 90% of CAH.
**What the screen will MISS or mishandle:**
| CAH subtype | Detected by 17-OHP NBS? |
|---|---|
| Classic 21-OHD (SW, SV) | **Yes** — high sensitivity if cut-offs are GA-adjusted |
| Non-classic 21-OHD | **Often missed** — 17-OHP not high enough at birth |
| 11β-OHD (CYP11B1-D) | Sometimes — 17-OHP may be mildly elevated |
| 17α-OHD (CYP17A1-D) | **No** — 17-OHP is low/normal |
| StAR-D, CYP11A1-D | **No** — all steroids low |
| 3β-HSD (HSD3B2-D) | May give **false positive** (cross-reactivity from high Δ5 steroids) |
| POR-D | Mildly elevated 17-OHP — easily missed or misclassified |
> Take-home: a **negative NBS does not rule out non-21-OHD CAH** in a sick or ambiguous newborn. Use [[cah-newborn-subtype-differentiator]].
---
## STEP 2 — Use gestational-age and birth-weight adjusted cut-offs
The single most common cause of NBS false positives is using a one-size-fits-all cut-off. Stressed, preterm, low-birth-weight, and sick newborns physiologically have higher 17-OHP.
**Each screening centre should publish its own cut-offs.** Typical tiered framework (adapt to local lab):
| Strata | Recommended action thresholds (DBS 17-OHP, nmol/L)* |
|---|---|
| **Term, > 2500 g, well** | Negative < 30; borderline 30–90; positive > 90 |
| **Preterm 32–36 wk OR 1500–2500 g** | Negative < 60; borderline 60–165; positive > 165 |
| **Preterm < 32 wk OR < 1500 g OR ICU/sick** | Negative < 120; borderline 120–270; positive > 270 |
> *Values are indicative — **use your local laboratory's GA- and BW-stratified cut-offs**. Conversion: 1 ng/mL ≈ 3 nmol/L.
**Timing of sample:** ideal between **48–72 h of life** (after the physiological 17-OHP fall). Samples taken < 24 h are unreliable.
---
## STEP 3 — Triage the result
### A. Clearly **negative** (below GA-stratified cut-off)
- No further CAH workup unless clinical suspicion (ambiguous genitalia, SW, hypoglycaemia, hyperpigmentation, family history).
- Remember: rule-out is only for 21-OHD.
### B. **Borderline** (intermediate band)
- **Repeat DBS** 17-OHP at 1–2 weeks of life.
- If second sample still borderline → run **second-tier LC-MS/MS** on the same blood spot or send a serum sample (see Step 4).
- Examine the baby — genitalia, hydration, electrolytes, BP.
### C. Clearly **positive** (above upper threshold)
- **Treat as a confirmed screen-positive immediately** — do not wait for repeat.
- Same day:
1. Clinical exam (genitalia, hydration, hyperpigmentation, glucose).
2. **Serum 17-OHP, electrolytes (Na, K), glucose, ACTH, cortisol, renin, aldosterone, androstenedione, testosterone**.
3. Karyotype if genitalia ambiguous.
4. **Pelvic / adrenal ultrasound** (look for adrenal hyperplasia, uterus in 46,XX virilised).
5. Counsel family — pending confirmation.
- If clinically unwell (SW, hypoglycaemia, shock) → manage as [[cah-adrenal-crisis-protocol]] and start hydrocortisone empirically **after** drawing baseline samples.
---
## STEP 4 — Use second-tier LC-MS/MS to cut the false-positive rate
A second-tier mass-spec panel on the original DBS punch dramatically improves the positive predictive value of NBS.
Typical panel:
- **17-OHP** (re-quantified)
- **21-deoxycortisol (21-DOF)** — the most specific marker for 21-OHD
- **Androstenedione (Δ4A)**
- **Cortisol (F)**
- Ratios: **(17-OHP + Δ4A) / F**; **21-DOF / F**
> An elevated **21-DOF** and a high (17-OHP + Δ4A)/F ratio strongly confirm CYP21A2-D and reduce false positives from stress, prematurity, and HSD3B2-D.
This is feasible in most national NBS labs in 2026; if not available locally, **send serum 17-OHP at 24 h after a screen-positive** alongside the rest of the work-up in Step 3.
---
## STEP 5 — Immediate clinical action plan for a positive screen
> Don't wait for confirmation if the baby is sick. Treat first, refine the diagnosis after.
1. **Examine** — genitalia (Prader stage), hydration, BP, hyperpigmentation, glucose.
2. **Sample** — electrolytes, glucose, serum 17-OHP, cortisol, ACTH, renin, aldosterone, androstenedione, testosterone, karyotype.
3. **Stabilise** — IV fluids, glucose; if any feature of crisis → IV hydrocortisone per [[cah-adrenal-crisis-protocol]].
4. **Start** treatment when confirmed (or empirically if sick) — see [[cah-infant-hydrocortisone-dosing]] and [[cah-fludrocortisone-salt-supplementation]].
5. **Family counselling** — diagnosis, lifelong replacement, sick-day rules, future pregnancy implications (autosomal recessive — 25% recurrence; offer genetic counselling).
6. **Issue the disease card** (see [[cah-adrenal-crisis-protocol]] Step 2).
---
## STEP 6 — Avoid these common errors
- **Anchoring on a single cut-off** across all GA/BW strata → false positives in preterms, false negatives in healthy terms.
- **Sampling before 24 h of life** → physiological elevation.
- **Assuming NBS rules out all CAH** — it does not (see Step 1).
- **Discharging a screen-positive baby** without exam and electrolytes — SW crisis can emerge in the 2nd week.
- **Starting hydrocortisone before drawing diagnostic samples** unless the baby is in crisis.
- **Failing to repeat** in a borderline preterm with persistent stress (still in NICU, sepsis, etc.).
---
## Quick reference
- NBS = **17-OHP on DBS at 48–72 h**.
- Detects **CYP21A2-D**; misses other forms.
- Use **GA-/BW-stratified cut-offs**.
- **Borderline** → repeat in 1–2 weeks + 2nd-tier LC-MS/MS.
- **Positive** → same-day clinical exam, electrolytes, serum panel, pelvic/adrenal US, karyotype if ambiguous.
- **Sick baby + positive screen** → treat as crisis first, refine diagnosis after samples are drawn.
- 21-DOF on LC-MS/MS is the **most specific** confirmatory marker.
---
## Related skills
- [[cah-newborn-subtype-differentiator]] — when the screen result and phenotype don't fit 21-OHD.
- [[cah-adrenal-crisis-protocol]] — for the sick screen-positive newborn.
- [[cah-infant-hydrocortisone-dosing]] — start maintenance therapy once confirmed.
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!